Canadian International Pharma Corp. Provides Company Update
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
News Release No: 17-01
Trading symbols: TSX-V - NEX: CIP.H
Canadian International Pharma Corp. Provides Company Update
West Vancouver, British Columbia, April 13, 2017 – Canadian International Pharma Corp. (the
“Company” or “CIPC”) – CIPC is pleased to provide an update on the Company’s ongoing efforts to
grow its business and to generate shareholder value.
PharmaCert Program
One of the Company’s major focuses is its PharmaCert Program. PharmaCert is a Canadian certification
program for finished dosage forms of nutraceutical and pharmaceutical medications manufactured
around the world . CIPC has received several expressions of interest from major international
manufacturers through its online registration system. The Company is working closely with these
manufacturers in an effort to generate contracts to provide the PharmaCert Program for their multiple
medications. For more information about the PharmaCert program, visit the C ompany’s dedicated
website at www.pharmacert.ca
Cross Licensing
CIPC cross licenses generic and nutraceutical medications manufactured by intern ational companies.
The Company can provide services to register these medications in North American markets. Once
registered, CIPC offers sales and marketing programs to promote these medications in Canadian and
US markets. CIPC is working closely with two prospective clients looking to expand into Canada. In
particular, we are in negotiations with one of the largest privately held pharmaceutical companies in
India with sales in over 85 countries, and a dental products company based in Barcelona, Spain. Initially,
if engaged, CIPC would provide services to assist these companies in obtaining the Drug Identification
Number (DIN) registrations required to sell medications in Canada, and subsequently assist in the sales
of the products.
Business Development Agents
CIPC continues to engage business development agents a s part of its plan to develop and generate
generic and nutraceutical sales for the Company in strategic regions worldwide. To date, the Company
has engaged seven Business Development Agents covering the Middle East, Europe, Dubai, Iran,
Egypt, India, and Lebanon, and will continue to engage qualified agents that can potentially provide
resources and quality business contacts to develop future sales in new territories.
Conference and Trade Show Presence
In an effort to develop business and to build stronger relationships with international manufacturing and
distribution companies, CIPC plans to attend several conferences and trade shows in the coming year.
At present, the Company’s management and its Business Development Agents are planning to attend
seven upcoming shows, including:
16th World Nano Conference: June 05-06, 2017 - Milan, Italy
http://nano.conferenceseries.com
Nanomedicine and Pharmaceutical Nanotechnology: July 24-25, 2017 - Rome, Italy
http://nanotechnology.pharmaceuticalconferences.com
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
Generic Drugs and Biosimilars: August 24-25, 2017 - Birmingham, UK
http://generic-market.pharmaceuticalconferences.com
Pharmaceutical Formulations:August 28-29, 2017 - Brussels, Belgium
http://formulation.pharmaceuticalconferences.com
12th Annual Pharma Middle East Congress:Sep 25-27, 2017 - Dubai, UAE
http://middleeast.pharmaceuticalconferences.com
WorldWide CPhI conference: 24 - 26 October 2017 - Frankfurt, Germany
http://www.cphi.com/europe/
4th European Biopharma Congress November 16-17, 2017 - Vienna, Austria
http://biopharmaceutics.pharmaceuticalconferences.com/europe/
About Canadian International Pharma Corp.
Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi -faceted
pharmaceutical company that is in the process of developing generic and nutraceutical drug
manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program.
PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical
and pharmaceutical medications. The Company has also aligned itself with Canadian and US
manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and
overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit
the Company’s website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
“Merun Payravi”
____________________________________________
Mehrun Payravi, President
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture
Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable
securities legislation . All statements, other than historical facts, are f orward-looking statements and are generally, but not
always, ide ntified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”,
”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. The
Company’s statements regarding business opportunities from its PharmaCert Program, its cross licencing business, the
engagement of its busines s development agents and attenda nces at upcoming conferenc e and trade shows are forward -
looking statements and a lthough the Company believes the expectations expressed in such forward -looking statements are
based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ
materially from those expressed in, or implied by, t his forward-looking information. Factors that could cause actual results to
differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated
products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and
general economic, market or business conditions. Any forward -looking statements are expressly qualified in their entirety by
this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
management on the date such statements were made. The Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein i n the
United States. The securities described herein have not been and will not be registered under the United States Securities Act
of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent
an exemption from the registration requirements of such Act.